Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing

12/01/2021 | 09:34am EST

CARLSBAD, Calif. - For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target editing efficiency. Thermo Fisher Scientific introduced the new protein to complement its growing portfolio of CRISPR genome editing solutions.

CRISPR genome editing is inherently messy, often resulting in edits in unintended locations. Limiting off-target effects is critical for applications such as translational research, drug screening and drug modeling as researchers look down the road to future therapeutic development. The Invitrogen TrueCut HiFi Cas9 Protein demonstrates near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), and demonstrates improved off-target profiles relative to other products on the market.

'Our pharma and biotech customers are looking for highly precise, accurate solutions to harness the power of CRISPR genome editing,' said Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific. 'Nothing is more disappointing than to find out months after an edit that the biological response you are measuring was due to an unintended off-target edit. The new Invitrogen TrueCut HiFi Cas9 Protein offers researchers the confidence that their edits took place where they intended, not somewhere else in the genome.'

Thermo Fisher's growing portfolio of genome editing tools also includes the recently redesigned Invitrogen TrueDesign Genome Editor, a free online tool to help scientists easily design their genome editing experiments. The software's predictive algorithm scores each guide RNA, giving scientists the insights they need to select the right materials to limit off-target effects and perform a successful edit. The Invitrogen TrueDesign Genome Editor supports experiment types including gene knockouts, fluorescent tagging, insertions, deletions, SNP edits and replacements.

To learn more about the Invitrogen TrueCut HiFi Cas9 Protein, visit thermofisher.com/cas9.

For more information on Thermo Fisher's full CRISPR genome editing portfolio, visit thermofisher.com/crispr.

For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.



Mauricio Minotta

Phone: 760-805-5266

Email: mauricio.minotta@thermofisher.com

(C) 2021 Electronic News Publishing, source ENP Newswire

04:06pThermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Cons..
01/26Barclays Reinstates Thermo Fisher Scientific at Overweight with $700 Price Target
01/21THERMO FISHER SCIENTIFIC INC. : Regulation FD Disclosure (form 8-K)
01/19Oncocyte Shares Drop 11% After Marketing Deal With Thermo Fisher
01/18OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology
01/18Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific..
01/11Thermo Fisher Scientific Exec Says Pricing Is Going To Be Higher In 2022 Than In Past Y..
01/11Thermo fisher scientific exec says pricing is going to be higher in 2022 than in past y..
01/11Thermo fisher scientific exec says demand for vaccines will be relevant at least into 2..
01/10SomaLogic Hires Adam Taich as Chief Business Officer
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 37 627 M - -
Net income 2021 7 855 M - -
Net Debt 2021 25 663 M - -
P/E ratio 2021 28,6x
Yield 2021 0,17%
Capitalization 218 B 218 B -
EV / Sales 2021 6,48x
EV / Sales 2022 5,84x
Nbr of Employees 80 000
Free-Float -
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 23
Last Close Price 562,90 $
Average target price 683,95 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors